Why the study?
The role of heart failure medications in transthyretin amyloid cardiomyopathy remains uncertain and challenging, with unknown effects on clinical outcomes such as mortality and hospitalization.
Does guideline-directed medical therapy for heart failure improve clinical outcomes in patients with transthyretin amyloid cardiomyopathy?
Does guideline-directed medical therapy for heart failure improve clinical outcomes in patients with transthyretin amyloid cardiomyopathy?
Answers are grounded in this paper and cite their sources.
The role of standard heart failure medications in ATTR-CM remains uncertain, necessitating a reassessment of current LVEF-based guideline recommendations for this specific patient population.
Cardiac amyloidosis is an underdiagnosed cause of infiltrative cardiomyopathy, leading to heart failure across the spectrum of ejection fractions. Although there are approved disease-modulating therapies for the transthyretin subtype (transthyretin amyloid cardiomyopathy [ATTR-CM]), the role of heart failure medications remains uncertain and challenging in clinical practice. Their effects on clinical outcomes, such as mortality and hospitalization, are unknown for ATTR-CM. This review aims to explore the use of these medications in ATTR-CM, considering the disease's stage and patient-specific issues, such as fluid homeostasis, autonomic dysfunction, conduction disorders, low and fixed stroke volumes, and decreased functional capacity. As our understanding of this condition deepens, it is important to reassess the impact of contemporary heart failure medication in ATTR-CM. Finally, the relevance of guideline recommendations for heart failure drugs based on left ventricular ejection fraction should be reconsidered in the context of ATTR-CM.
No takes yet. Share an insight, caveat, or question.
Schwarting et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: